Antimicrobial Resistance Threats in the emerging COVID-19 pandemic: Where do we stand?

被引:117
|
作者
Ghosh, Soumya [1 ]
Bornman, Charne [1 ]
Zafer, Mai M. [2 ]
机构
[1] Univ Free State, Fac Nat & Agr Sci, Dept Genet, Bloemfontein, South Africa
[2] Ahram Canadian Univ, Fac Pharm, Dept Microbiol & Immunol, Giza, Egypt
关键词
Antimicrobial resistance; COVID-19; Secondary bacterial infection; Stewardship; PNEUMONIA; INFLUENZA; STEWARDSHIP; PATHOGENS; WUHAN;
D O I
10.1016/j.jiph.2021.02.011
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Antimicrobial resistance (AMR) continues to exert a substantial toll on the global health and world economy and is now expected to be hidden by COVID-19 for a while. The wrong consumption of antibiotics during the COVID-19 pandemic will raise disastrous effects on AMR management and antibiotic stewardship programs. This is related to the concerns extrapolated due to an increase in mortality rates in patients with bacterial coinfections. Importantly, the immune system of COVID-19 patients in regions with high AMR may be fighting on two fronts altogether, the virus and MDR bacteria. Current control policies to manage AMR and prioritization of antibiotic stewardship plans are mandatory during this pandemic. This review aims to discuss the rising concerns of the excess use of antibiotics in COVID-19 patients highlighting the role of bacterial coinfections in these patients. Types of prescribed antibiotics and the development of antibiotic resistance is addressed as well. (c) 2021 Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/bync-nd/4.0/).
引用
收藏
页码:555 / 560
页数:6
相关论文
共 50 条
  • [1] COVID-19 pandemic and cardiovascular disease: where do we stand?
    Chatzis, Dimitrios G.
    Magounaki, Kalliopi T.
    Pantazopoulos, Ioannis N.
    Johnson, Elizabeth O.
    Tsioufis, Konstantinos P.
    [J]. MINERVA CARDIOANGIOLOGICA, 2020, 68 (04): : 347 - 358
  • [2] Myocarditis and COVID-19: Where Do We Stand?
    Jakstaite, Aiste Monika
    Papathanasiou, Maria
    Luedike, Peter
    [J]. AKTUELLE KARDIOLOGIE, 2021, 10 (01) : 27 - 31
  • [3] COVID-19 and AKI: Where Do We Stand?
    Palevsky, Paul M.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (05): : 1029 - 1032
  • [4] COVID-19 in Children: Where do we Stand?
    Nikolopoulou, Georgia B.
    Maltezou, Helena C.
    [J]. ARCHIVES OF MEDICAL RESEARCH, 2022, 53 (01) : 1 - 8
  • [5] COVID-19 vaccines: Where do we stand?
    Tulay, Pinar
    Ergoren, Mahmut Cerkez
    Dundar, Munis
    [J]. EUROBIOTECH JOURNAL, 2021, 5 (01): : 13 - 16
  • [6] Chloroquine and COVID-19, where do we stand?
    Lecuit, M.
    [J]. MEDECINE ET MALADIES INFECTIEUSES, 2020, 50 (03): : 229 - 230
  • [7] Antimicrobial resistance in the emerging COVID-19 pandemic
    Jaiswal, Abhishek
    Jaiswal, Ankita
    Puri, Surabhi
    Pal, Adarsh
    [J]. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2021, 50 : 113 - 113
  • [8] Vaccines for COVID-19: Where do we stand in 2021?
    Sharma, Ketaki
    Koirala, Archana
    Nicolopoulos, Katrina
    Chiu, Clayton
    Wood, Nicholas
    Britton, Philip N.
    [J]. PAEDIATRIC RESPIRATORY REVIEWS, 2021, 39 : 22 - 31
  • [9] Covid-19 and perioperative mortality; where do we stand?
    Shakiba, Behnam
    Irani, Shirin
    [J]. ECLINICALMEDICINE, 2020, 22
  • [10] Superadded Coinfections and Antibiotic Resistance in the Context of COVID-19: Where do We stand?
    Kayarat, Bhavana
    Khanna, Puneet
    Sarkar, Soumya
    [J]. INDIAN JOURNAL OF CRITICAL CARE MEDICINE, 2021, 25 (06) : 698 - 702